The primary results from the Lp(a)HORIZON trial were presented at the AHA Scientific Sessions in Chicago on November 7, 2026. Although pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the trial did not reduce the risk of major adverse cardiovascular events (MACE). Lp(a) remains an important and independent risk factor for ASCVD, so what comes next?
In this Lipid Insights episode, host Peter H. Jones, MD, MNLA sits down with two leading Lp(a) experts, Michael B. Boffa, PhD, and Marlys L. Koschinsky, PhD, FNLA, to react to the results and discuss what they mean for Lp(a) in cardiovascular prevention.
A timely listen for anyone looking to understand where Lp(a) science and clinical practice go from here.
